Montelukast Generics [uk] (Montelukast)

Montelukast works by selectively blocking the cysteinyl leukotriene receptor CysLT1. This inhibition prevents leukotrienes, which are inflammatory mediators, from causing bronchoconstriction, mucus production, and airway swelling, thereby improving breathing and reducing allergic inflammation.

The appropriate dose of Montelukast is determined by a qualified prescriber based on the patient’s age, condition, and clinical response. Dosage may differ for asthma maintenance, allergic rhinitis, or exercise‑induced bronchoconstriction, and should always follow the healthcare professional’s instructions.

Montelukast is classified as Pregnancy Category B, indicating no evidence of risk in animal studies but limited human data. It may be used during pregnancy only if the potential benefit justifies the risk. Small amounts are excreted in breast milk; breastfeeding decisions should consider the infant’s benefit versus maternal need.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids and long‑acting beta‑agonists. While it is effective for maintenance therapy and allergy control, it is generally used as an add‑on rather than a sole replacement for inhaled steroids in moderate‑to‑severe asthma.

Montelukast Generics should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in their original container, protect them from moisture, heat and direct sunlight to maintain potency throughout the shelf life.

Montelukast is taken orally, usually once daily in the evening, with or without food. The tablet should be swallowed whole with a glass of water. Specific timing and administration instructions are provided by the prescribing clinician.

Serious risks, though rare, include neuropsychiatric events such as mood changes, depression, or suicidal thoughts, as well as severe allergic reactions like rash, urticaria, or angioedema. Patients should seek immediate medical attention if they experience any of these symptoms.

Montelukast is contraindicated in individuals with known hypersensitivity to the drug or any of its excipients. Caution is advised for patients with a history of neuropsychiatric disorders, severe hepatic impairment, or those taking interacting medications that may alter its effectiveness.